ArticleEuropean archives of psychiatry and clinical neuroscience2026
Role of emotional intelligence in schizophrenia: ability-based vs. self-reported assessment.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBoth ability-based tests (such as Mayer-Salovey-Caruso Emotional Intelligence Test-the managing emotions branch [MSCEIT-ME]) and self-reported scales (such as Wong and Law Emotional Intelligence Scale [WLEIS]) have been employed to measure emotional intelligence (EI). While the clinical relevance of MSCEIT-ME performance among schizophrenia patients appeared inconsistent across studies, the role of WLEIS in schizophrenia has not yet been investigated.
methodsWe examined the effect of WLEIS scores on MSCEIT-ME performance in 492 Taiwanese schizophrenia patients (including 92 drug-free and 400 chronic medicated patients), and then the influence of symptomatology and neurocognition (with nine cognitive tests) on EI (MSCEIT-ME or WLEIS). Finally, we explored the differential roles of the two EI instruments in functional outcome (Global Assessment of Functioning [GAF] Scale and the Quality of Life [QoL] Scale).
resultsWith multiple regression analyses, participants' WLEIS performance showed a positive correlation with MSCEIT-ME scores after controlling sex and age. While male and younger patients with better nonverbal working memory and less severe negative symptoms were more likely to have better MSCEIT-ME performance, older patients with more positive symptoms and fewer depressive symptoms showed greater WLEIS performance. Moreover, female and younger individuals with better MSCEIT-ME and WLEIS scores had more favorable QoL, while higher MSCEIT-ME scores linked to patients' better GAF. In addition, patients' medication status didn't affect the aforementioned findings.
conclusionThe results suggest that that MSCEIT-ME and WLEIS may differ in their associations with clinical and neurocognitive profiles, and their impacts on functional outcome. Longitudinal studies in other populations are warranted.
Indexed as
Identifiers
41269290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.